Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes

Burkitt lymphoma (BL) is classified into 3 clinical subsets: endemic, sporadic, and immunodeficiency-associated BL. So far, possible differences in their gene expression profiles (GEPs) have not been investigated. We studied GEPs of BL subtypes, other B-cell lymphomas, and B lymphocytes; first, we f...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 117; no. 13; pp. 3596 - 3608
Main Authors Piccaluga, Pier Paolo, De Falco, Giulia, Kustagi, Manjunath, Gazzola, Anna, Agostinelli, Claudio, Tripodo, Claudio, Leucci, Eleonora, Onnis, Anna, Astolfi, Annalisa, Sapienza, Maria Rosaria, Bellan, Cristiana, Lazzi, Stefano, Tumwine, Lynnette, Mawanda, Michael, Ogwang, Martin, Calbi, Valeria, Formica, Serena, Califano, Andrea, Pileri, Stefano A., Leoncini, Lorenzo
Format Journal Article
LanguageEnglish
Published Washington, DC Elsevier Inc 31.03.2011
Americain Society of Hematology
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Burkitt lymphoma (BL) is classified into 3 clinical subsets: endemic, sporadic, and immunodeficiency-associated BL. So far, possible differences in their gene expression profiles (GEPs) have not been investigated. We studied GEPs of BL subtypes, other B-cell lymphomas, and B lymphocytes; first, we found that BL is a unique molecular entity, distinct from other B-cell malignancies. Indeed, by unsupervised analysis all BLs clearly clustered apart of other lymphomas. Second, we found that BL subtypes presented slight differences in GEPs. Particularly, they differed for genes involved in cell cycle control, B-cell receptor signaling, and tumor necrosis factor/nuclear factor κB pathways. Notably, by reverse engineering, we found that endemic and sporadic BLs diverged for genes dependent on RBL2 activity. Furthermore, we found that all BLs were intimately related to germinal center cells, differing from them for molecules involved in cell proliferation, immune response, and signal transduction. Finally, to validate GEP, we applied immunohistochemistry to a large panel of cases and showed that RBL2 can cooperate with MYC in inducing a neoplastic phenotype in vitro and in vivo. In conclusion, our study provided substantial insights on the pathobiology of BLs, by offering novel evidences that may be relevant for its classification and possibly future treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2010-08-301556